Management of hypertension, and dyslipidemia

被引:20
作者
Ferdinand, Keith C. [1 ]
Kleinpeter, Myra A. [1 ]
机构
[1] Assoc Black Cardiol Inc, Atlanta, GA 30349 USA
关键词
D O I
10.1007/s11906-006-0028-5
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Cardiovascular disease, the leading cause of death in the United States and other developed societies, can be managed with intensive risk factor modification, including treatment of hypertension and dyslipidemia. Evidence for reduction of cardiovascular morbidity and mortality is summarized in evidence-based guidelines' primarily for hypertension in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and for dyslipidemia in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Many medications exist for treatment of hypertension and a limited number for dyslipidemia; the cornerstone of therapy for both remains lifestyle modification, including dietary interventions. Despite guidelines, control rates of concomitant hypertension and dyslipidemia remain low. Patient adherence may affect achievement of recommended goals of therapy for dyslipidemia and hypertension. Effective education and communication may improve overall achievement of treatment goals.
引用
收藏
页码:489 / 496
页数:8
相关论文
共 44 条
[1]   Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
DIABETIC MEDICINE, 2006, 23 (05) :469-480
[2]  
*AM HEART ASS, 2006, HEART DIS STROK STAT
[3]   Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure [J].
Angus, DC ;
Linde-Zwirble, WT ;
Tam, SW ;
Ghali, JK ;
Sabolinski, ML ;
Villagra, VG ;
Winkelmayer, WC ;
Worcel, M .
CIRCULATION, 2005, 112 (24) :3745-3753
[4]  
[Anonymous], 1991, JAMA, V265, P3255
[5]  
[Anonymous], 2002, JAMA
[6]  
[Anonymous], HEART DIS TXB CARDIO
[7]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[8]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   ALLHAT: Setting the record straight [J].
Davis, BR ;
Furberg, CD ;
Wright, JT ;
Cutler, JA ;
Whelton, P .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (01) :39-46